Carfilzomib acts as a novel proteasome inhibitor utilized in the fight against cancer. It medication operates by interfering with the activity of the Carfilzomib for relapsed MM proteasome, a cellular structure responsible for the destruction of proteins. By inhibiting this function, carfilzomib leads the buildup of damaged or abnormal proteins, ul

Tepotinib, also known as {MSC2156119|the research compound|this molecule), represents a promising step in the targeting of lung condition, particularly in patients harboring MET changes. This targeted tyrosine kinase blocker|TKI demonstrates considerable efficacy against cancer expansion in laboratory assessments and first human evaluations. Its me

Teclistamab serves as a revolutionary novel anti-BCMA antibody drug compound, designated JNJ-64007957, featuring immense potential in the treatment of multiple myeloma. This innovative therapeutic operates by specifically targeting BCMA, a marker highly present on the surface of myeloma cells. Through this precise strategy, teclistamab transmits a